David B Agus

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

Brian Higgins, H. Scher, M. Sliwkowski, 2002, Cancer cell.

Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy.

David S Mendelson, M. Morris, H. Scher, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical proteomics: the promises and challenges of mass spectrometry-based biomarker discovery.

Jonathan E Katz, D. Agus, J. Katz, 2006, Clinical advances in hematology & oncology : H&O.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Quynh-Thu Le, Martin G Pomper, Levi Garraway, 2017, The Lancet. Oncology.

The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells

William Pao, Franziska Michor, Kevin Leder, 2015, Cancer informatics.

Multiparameter computational modeling of tumor invasion.

Mauro Ferrari, Vittorio Cristini, John S Lowengrub, 2009, Cancer research.